Thursday, September 5, 2013
Publication and contact
Fourteen-step synthesis of ingenol
to aid analog design
14-step process for ingenol synthesis could facilitate the generation of
analogs for therapeutic evaluation. Ingenol is a diterpenoid, and analogs of
the molecule are marketed to treat cancer. However, ingenol currently is
obtained directly from its plant source with an isolation yield of about
0.028% by weight. In the new approach, a 2-phase, 14-step chemical synthesis,
starting from the inexpensive commodity chemical 3-carene,
generated ingenol with a 1.2% overall yield. Next steps include optimizing
the final steps of the process and trying to further decrease the number of
Pharma A/S markets Picato
mebutate gel, an ingenol 3-angeloyl topical
formulation, to treat actinic keratosis. The topical drug also is in Phase II
testing to treat basal cell carcinoma (BCC).
Published online Sept. 5, 2013
application filed; licensing details available from Leo Pharma
Jørgensen, L. et al.
published online Aug. 1, 2013;
Contact: Phil S. Baran, The Scripps Research Institute, La
Contact: Steve J. McKerrall,
same affiliation as above
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]